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The medical community increasingly supports the use of simplifying constructs or ratios to
facilitate incorporation of evidence-based medicine into clinical practice such as number
needed to treat (NNT) and polarity index (PI). Clinicians and teachers ﬁnd them to be an
appealing, easy-to remember integer that can be readily translated into clinical practice.
However, serious questions have been raised with respect to the validity, reliability and value of
these descriptors of response. This commentary identiﬁes some of the speciﬁc limitations of the
NNT and PI constructs when applied to treatments of bipolar disorder.
& 2013 Elsevier B.V. and ECNP. Open access under CC BY-NC-ND license.1. Introduction
The medical community increasingly supports the use of
simplifying constructs or ratios to facilitate incorporation of
evidence-based medicine into clinical practice. Clinicians
and teachers ﬁnd them to be an appealing, easy-to-
remember integer that can be readily translated into
clinical practice. Among these constructs are: the number
needed to treat (NNT) (Citrome, 2012, 2010; Popovic et al.,NP.
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Open access under CC BY-NC-ND l2011), number needed to harm (NNH), and the likelihood to
be helped or harmed (the ratio of NNH to NNT) (Citrome and
Katrowitz, 2008; Citrome, 2012). Recently, Popovic et al.
(2012) have proposed the polarity index (PI) as another
descriptor for categorizing proﬁles of drugs used for main-
tenance treatment of bipolar disorder. This PI is derived by
dividing the NNT for the prevention of depressive episodes
by the NNT for the prevention of manic episodes (Popovic
et al., 2012).
Despite their apparent utility, serious questions have
been raised with respect to the validity, reliability and
value of these descriptors of response (Hutton, 2000;
Thabane, 2003; Stang et al., 2010; Suissa et al., 2012).
We argue that particularly in complex diseases such as
bipolar disorder, which have a heterogeneous presentation,
natural history, and response to treatment (e.g., multipleicense.
L. Alphs et al.1598potential outcomes, large variability in response, and
numerous competing risks for recurrence of mood episodes
during maintenance treatment), the limitations of these
constructs, especially those expressed as ratios and ratios of
ratios, are exaggerated and severely restrict or nullify their
clinical utility. Indeed, it is unlikely that any single measure
can ever summarize the full spectrum of therapeutic
responses to maintenance treatment for the full population.
This commentary identiﬁes some of the speciﬁc limitations
of the NNT and PI constructs when applied to treatments of
bipolar disorder.
Inherent in these constructs is a lack of clarity as to their
true statistical properties, especially when presented with-
out conﬁdence intervals (CIs). For example, they provide no
information on the normality or skewness of the population
under consideration (Hutton, 2000; Lesaffre and Pledger,
1999). Further, without knowledge that treatment response
is stable within key population subgroups (like those for age,
sex, race, co-morbidities, etc.) the use of these constructs
in clinical decision-making or meta-analysis is unwise or
even dangerous (Smeeth et al., 1999) as their use may drive
decisions contrary to the observed effects in these popula-
tion subgroups.
A speciﬁc example that highlights these challenges is the
PI. It has been developed to summarize, in a single, easily
remembered number, both the relative antimanic and
antidepressant preventive potentials of pharmacologic
treatments, and facilitate clinical decision-making regard-
ing selection of maintenance treatment. However, its
derivation is based on numerous unsupported assumptions.
Among these are that: (1) there is a single, well-accepted
deﬁnition of relapse that has been consistently applied to
the studies from which this number is derived; (2) the risk of
relapse is consistent for all members of that population over
the course of the disorder; and (3) if a PI is being generated
from a meta-analysis of different studies, the true mean for
those studies is similar and is derived from similar popula-
tions such that data collected in separate studies can be
validly pooled.
Even assuming a ﬁxed deﬁnition of relapse across studies;
the baseline risk of relapse almost certainly varies across
subpopulations and at different points within the course of
the disease. For instance, one cannot assume that the
baseline risk for relapse for adolescents with bipolar
disorder is the same as that for elderly persons with a long
history of the disease. Nor is the baseline risk for relapse in
persons who have less than one month of recovery from a
depressive relapse likely to be identical to that for persons
who have not had any relapses in the past year. This argues
against combining results across trials to generate a meta-
analytically-derived PI.
To illustrate and clarify this scenario, let us assume
Treatment A for bipolar disorder provides a constant 50%
risk reduction for relapse across the disease spectrum
compared to placebo. If we know that the annualized risk
of relapse in an adolescent with a recent relapse treated
with placebo is 60%, then the risk for relapse in this person
receiving Treatment A is 30%, with an absolute risk reduc-
tion of 30% and an NNT of 1/0.3=3.33. However, if the
annualized risk of relapse in an elderly person with no
history of relapse in the past two years treated with placebo
is 20%, then the risk for relapse in this person receivingTreatment A is 10%, with an absolute risk reduction of 10%
and an NNT of 1/0.1=10. What, then, is the NNT for
Treatment A? Can we combine the results from two such
different groups of patients to give an NNT for the entire
population? This is complicated even further by emerging
evidence that the effect of psychotropic medication on
biomarkers reﬂective of the course of the underlying
psychiatric disorder is not constant over the disease spec-
trum (Bartzokis, 2012). For instance, Treatment A may be
more effective early in the course of bipolar disorder than
later in the disease course. These considerations raise the
requirement for including a CI with each NNT as discussed
below. For this example a CI would be required for the
constant risk reduction, and the risks for relapse in each
subpopulation.
We argue that existing data suggest that the NNT for
relapse into mania and relapse into depression differ
according to factors such as the polarity of the index
episode, number of previous episodes, time since last
episode, baseline severity of mood symptoms, and other
factors. When identiﬁed from clinical trials, these summary
characteristics may be further inﬂuenced by dropout rates,
treatment adherence characteristics, and duration of pro-
spective follow-up (e.g., values may be different after one
month of follow up versus one year of follow up). We
contend that all of these factors can impact response to
treatment and, consequently, could affect NNT-derived
constructs. To identify a number that adequately represents
the entire population, all risk factors affecting relapse must
be known or predicted with signiﬁcant conﬁdence. We argue
that it is impossible to address all of these factors so as to
construct a single valid PI for the entire population. Even if
this could be achieved, it would be impossible for a clinician
to unravel this information when attempting to use the PI to
choose between Treatment A and Treatment B for treat-
ment of a substance-abusing 30-year-old bipolar patient
with a history of manic relapse six months ago.
Beyond these difﬁculties, the quantitative/statistical
shortcomings of the PI are substantial. Among these are:
1.1. Problems with precision
As noted above, it cannot be assumed that everyone in the
population will respond identically at the point estimate
identiﬁed by the constituent NNTs. Presentation of a PI
(composed of two NNTs) as a point estimate without accom-
panying estimates of precision (e.g., a 95% CI) represents an
incomplete description of the therapeutic effect and fails to
provide the range of likely values for the population. It also fails
to rule out values that are outside of these plausible values. It
does not account for the greater certainty in range of possible
values that may be established in a large, well-conducted study
versus the lesser certainty of values derived from smaller
studies. Additionally, as a PI would be developed from separate
studies the CI for the numerator may differ substantially from
that of the denominator.
1.2. Problems when the CI estimate includes zero
A non-signiﬁcant NNTwill have a CI with two parts: one that
describes risk for harm, and the other, potential for beneﬁt.
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corresponding CI for the NNT includes inﬁnity. It is unclear
how both risk for harm and beneﬁt can be managed in a
single PI computation when either of the CIs includes zero.
How informative is a PI of 5, if the NNT for prevention of
depressive episodes is 10 (95% CI: 7 to 17) and the NNT for
prevention of manic episodes is 2 (95% CI: 15 to 10)? This
issue is further highlighted by situations where the treat-
ment effect on the risk for relapse into mania is opposite
the effect on depression. A PI so generated would not be
informative about which effect was inferior.
1.3. Problems with competing risks
The endpoint for the PI consists of two (not including a
separate category for mixed episodes) distinct events of
interest (relapse into mania and relapse into depression).
The eventual treatment failure is attributed to one event
exclusive of the other. This raises a problem of ‘competing
risks.’ Depressive and manic NNTs in clinical trial settings
are not independent. If a failure is attributed to one event
(e.g., depression), the chance for relapse into the other
event type (i.e., mania) is excluded. This is a typical
example of dependent censoring, and represents a version
of ascertainment bias in epidemiology.
1.4. Problems with using a simple proportion
The PI construct represents ratios of simple proportions that
capture event rates at the end of a deﬁned period.
However, it does not adjust for dropouts or censoring
mechanisms that are likely to have occurred during the
period of observation.
Historically, constructs such as the NNT, NNH, and their
ratios have been advocated for ascribing risks and beneﬁts
to treatments in acute disorders such as infection that
involve a homogeneous population with a circumscribed
outcome of interest (e.g., Helicobacter pylori eradication).
These characteristics and a uniform population response
have mitigated against misinterpretation of these simpliﬁed
constructs. However, with more complex disorders like
bipolar disorder, the variability in therapeutic effect across
patients and over time, the multiplicity of effects and
resulting permutations of possible results as well as the
sampling and statistical problems of the NNTand the PI limit
the utility of PI as a single conceptually meaningful mea-
sure. Indeed, an adequate presentation of these values
would require a spectrum of values that are likely to be so
broad and require so many qualiﬁers as to provide minimal
clinical utility.
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